Clinical trials: Desmoid, open to volunteers
Desmoid Tumor
Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
"Wait \& see" is currently the standard of care of recently diagnosed desmoid tumors (DT). In case of progression or symptomatic disease, medical therapy is nowadays widely used including chemotherapy.
- Trial name
- CRYODESMO-02 (NCT06081400)
- Testing
- Cryoablation, Chemotherapy drug
- Where
- 13 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Strasbourg, France
Familial Adenomatous Polyposis
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
This is a multicenter, two-part trial in participants with FAP.
- Trial name
- TUPELO (NCT05552755)
- Testing
- REC-4881
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Desmoid-Type Fibromatosis
Immunological Phenotype of Desmoid-fibromatosis-affected Patients.
This observational study aims to characterize the molecular, phenotypic, and functional inflammatory and immunological profile of patients with sporadic desmoid-type fibromatosis undergoing either active surveillance or systemic…
- Trial name
- NCT07496242
- Where
- 8 sites in Italy, Netherlands
- Volunteers
- 200 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Desmoid
Cryotherapy in the Treatment of Desmoid Tumors
Desmoid tumor is a benign neoplasm with an unpredictable course and a high rate of local recurrence if treated surgically. Therefore, over time the surgical approach has become conservative, preferring simple observation or…
- Trial name
- NCT05091255
- Testing
- Cryotherapy
- Where
- Italy
- Volunteers
- 94 people
- Sponsor
- Istituto Ortopedico Rizzoli
Desmoid Fibromatosis
Treatment of Desmoid Fibromatosis With Arterial Embolization
Desmoid fibromatoses are rare and locally aggressive mesenchymal tumors. The current scientific evidence regarding the efficacy and safety of the treatment of desmoid fibromatosis by arterial embolization is constituted by…
- Trial name
- TAE-DESMO (NCT06945887)
- Testing
- embolization therapy
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Ortopedico Rizzoli
Desmoid Fibromatosis
Observing People With Desmoid-Type Fibromatosis
The purpose of this study is to closely observe people with desmoid-type fibromatosis over 1 months.
- Trial name
- NCT04281381
- Testing
- Cross-sectional imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Desmoid
Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation
Desmoid tumors (DT) are uncommon tumors that arise from musculoaponeurotic structures. Despite benign, they can cause pain and disability due to their tendency to be locally aggressive.
- Trial name
- Cryomics (NCT06224283)
- Testing
- Cryoablation
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Istituto Ortopedico Rizzoli
The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an, Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After
Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors
The purpose of this study is to evaluate the efficacy of preoperative 5-ALA oral administration and subsequently intraoperative tumor bed phototherapy with red light laser, as an adjuvant therapy on the 3 years rate of local…
- Conditions
- The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an, Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After, Surgical Resection
- Trial name
- NCT01898416
- Testing
- 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
- Where
- 2 sites in Israel
- Volunteers
- 140 people
- Sponsor
- michal roll
Desmoid Tumor, Aggressive Fibromatoses
Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors
This study will evaluate patient-reported outcomes before and after percutaneous ablation of desmoid tumors. Adult participants undergoing ablation for desmoid tumor will complete surveys pre and post procedure to assess symptom…
- Trial name
- NCT07755176
- Testing
- Desmoid tumor ablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Desmoid Tumor, Aggressive Fibromatosis
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.
- Trial name
- NCT07176689
- Testing
- Nirogacestat
- Where
- 23 sites in Belgium, Germany and 4 more
- Volunteers
- 50 people
- Sponsor
- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Desmoid Tumor
Study of Cryoablation and Nirogacestat for Desmoid Tumor
The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.
- Trial name
- NCT05949099
- Testing
- Nirogacestat, Cryoablation
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Nam Bui
Cancer, Colorectal Cancer
FOG-001 in Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
- Conditions
- Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor
- Trial name
- NCT05919264
- Testing
- FOG-001, mFOLFOX-6, Nivolumab
- Where
- 33 sites in United States, Australia
- Volunteers
- 619 people
- Sponsor
- Parabilis Medicines, Inc.
Tumor
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
To learn about the safety and effects of an investigational drug called nirogacestat when given to participants with a desmoid tumor/aggressive fibromatosis
- Trial name
- NCT05879146
- Testing
- Nirogacestat
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Carcinoma, Endometrial Carcinoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma
- Trial name
- NCT04851119
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint
- Where
- 21 sites in United States
- Volunteers
- 147 people
- Sponsor
- Children's Oncology Group
Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan…
- Conditions
- Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor, Gastrointestinal Stromal Tumors, Ovarian Germ Cell Tumor
- Trial name
- SUR-CAN (NCT05500391)
- Testing
- Oncological Follow-up
- Where
- 3 sites in France
- Volunteers
- 88 people
- Sponsor
- Centre Oscar Lambret
Adrenal Gland Pheochromocytoma, Carcinoma In Situ
Project: Every Child for Younger Patients With Cancer
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and…
- Conditions
- Adrenal Gland Pheochromocytoma, Carcinoma In Situ, Central Nervous System Neoplasm, Childhood Immature Teratoma
- Trial name
- NCT02402244
- Testing
- Cytology Specimen Collection Procedure, Medical Chart Review
- Where
- 279 sites in United States, Australia and 4 more
- Volunteers
- 75,000 people
- Sponsor
- Children's Oncology Group
Desmoid Tumor, Desmoid Fibromatosis
A Prospective Clinical Study on the Safety and Efficacy of Radiofrequency Ablation for the Treatment of Patients With Desmoid Tumors
This is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors. In the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated…
- Conditions
- Desmoid Tumor, Desmoid Fibromatosis, Desmoid
- Trial name
- RFAdesmoid (NCT06355921)
- Testing
- radiofrequency ablation
- Where
- Russia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Blokhin's Russian Cancer Research Center
Soft Tissue Sarcoma, Desmoid Tumors
HIFU Ablation of Soft Tissue Sarcoma
Around 3,300 people are diagnosed with soft tissue sarcoma (STS) each year in the UK, and a significant proportion of STS diagnoses are in people aged under 30 years.
- Trial name
- SarcAblate (NCT05111964)
- Testing
- High Intensity Focused Ultrasound Ablation, Tumour Biopsy and Venous Blood Tests
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Oxford University Hospitals NHS Trust
Desmoid Tumor
A Study in Adults With Desmoid Tumors
This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics…
- Trial name
- NCT07541430
- Testing
- ES014
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
Sarcoma
Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma
This is a Phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin as first, second or third line therapy for advanced sarcoma, including desmoid tumor and chordoma.
- Trial name
- TNT (NCT03886311)
- Testing
- Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sarcoma Oncology Research Center, LLC